Goldman Sachs Upgrades Genmab on Strong 2026 Catalyst Outlook

Goldman Sachs has upgraded its stock rating for Genmab A/S (GMAB), citing the company's strong catalyst outlook for 2026. The investment bank anticipates that progress in Genmab's drug development pipeline and potential new product launches will support the company's growth potential. Goldman Sachs analysts noted that positive developments in Genmab's current drug pipeline, along with key clinical data readouts and regulatory submissions expected in 2026, will contribute to the stock's performance. These catalysts could lead to an upward revision in the company's market valuation. Genmab is particularly known for its innovative antibody therapies in oncology. The company is expected to achieve significant milestones by 2026 through its existing partnerships and internally developed drug candidates. Goldman Sachs' upgrade is seen as a reflection of these expectations. This is not investment advice.

📊 GS — Piyasa Yorumu

▲ up · 60%

Goldman Sachs' upgrade of Genmab reflects the firm's own positive analysis, potentially providing indirect support for GS shares. However, technical indicators paint a weak short-term picture: RSI at 45 is in neutral territory, MACD is below the signal line, and the price is trading below both the 20- and 50-day moving averages. While the news is positive, the current technical structure and recent daily decline suggest that any upside may be limited. Therefore, I have a mildly bullish expectation.

RSI 14

45.0

MACD

-0.32

24h Δ

-0.65%

Canlı Grafikler